Literature DB >> 29400707

IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis.

Yuejin Liang1, Panpan Yi2,3, Denley Ming Kee Yuan2, Zuliang Jie2, Zakari Kwota2, Lynn Soong2,4, Yingzi Cong2,4, Jiaren Sun5,6.   

Abstract

Viral hepatitis is still a public health problem affecting several million people around the world. Neutrophils are polymorphonuclear cells that have a critical role in antibacterial infection. However, the role of neutrophils in viral infection is not fully understood. By using a mouse model of lymphocytic choriomeningitis virus infection-induced viral hepatitis, we observed increased neutrophil recruitment in the liver accompanied by enhanced CD8+ T-cell responses. Liver neutrophils expressed high levels of immunomodulatory cytokines, such as C-X-C chemokine ligand 2, arginase-1, inducible nitric oxide synthase and interleukin (IL)-10, demonstrating immunosuppressive properties. Depletion of neutrophils in vivo by a neutralizing antibody resulted in the exacerbation of liver injury and the promotion of T-cell responses at the immune contraction stage. IL-33 significantly induced neutrophil recruitment in the liver and attenuated liver injury by limiting effector T-cell accumulation. Mechanistically, we found that IL-33 promoted the expression of arginase-1 in neutrophils through the type 2 innate lymphoid cell (ILC2)-derived IL-13. Additionally, IL-13 increased the inhibitory effect of neutrophils on CD8+ T-cell proliferation in vitro, partially through arginase-1. Finally, we found that IL-13 induced arginase-1 expression, depending on signal transducer and activator of transcription factor 6 (STAT6) signaling. Therefore, IL-33 induced immunosuppressive neutrophils via an ILC2/IL-13/STAT6 axis. Collectively, our findings shed new light on the mechanisms associated with IL-33-triggered neutrophils in the liver and suggest potential targets for therapeutic investigation in viral hepatitis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29400707      PMCID: PMC6355846          DOI: 10.1038/cmi.2017.147

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  63 in total

1.  Chronic but not acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-specific T cell immunity.

Authors:  Brian A Norris; Luke S Uebelhoer; Helder I Nakaya; Aryn A Price; Arash Grakoui; Bali Pulendran
Journal:  Immunity       Date:  2013-02-21       Impact factor: 31.745

Review 2.  The role of tissue resident cells in neutrophil recruitment.

Authors:  Nancy D Kim; Andrew D Luster
Journal:  Trends Immunol       Date:  2015-08-18       Impact factor: 16.687

Review 3.  Interleukin 33 is a guardian of barriers and a local alarmin.

Authors:  Nikolas T Martin; Michael U Martin
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

Review 4.  IL-4/IL-13 signaling beyond JAK/STAT.

Authors:  H Jiang; M B Harris; P Rothman
Journal:  J Allergy Clin Immunol       Date:  2000-06       Impact factor: 10.793

5.  Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.

Authors:  Steven L Highfill; Paulo C Rodriguez; Qing Zhou; Christine A Goetz; Brent H Koehn; Rachelle Veenstra; Patricia A Taylor; Angela Panoskaltsis-Mortari; Jonathan S Serody; David H Munn; Jakub Tolar; Augusto C Ochoa; Bruce R Blazar
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

6.  IL-33 promotes innate IFN-γ production and modulates dendritic cell response in LCMV-induced hepatitis in mice.

Authors:  Yuejin Liang; Zuliang Jie; Lifei Hou; Panpan Yi; Wei Wang; Zakari Kwota; Maria Salvato; Rene de Waal Malefyt; Lynn Soong; Jiaren Sun
Journal:  Eur J Immunol       Date:  2015-08-28       Impact factor: 5.532

7.  The interleukin-4 receptor activates STAT5 by a mechanism that relies upon common gamma-chain.

Authors:  A Lischke; R Moriggl; S Brändlein; S Berchtold; W Kammer; W Sebald; B Groner; X Liu; L Hennighausen; K Friedrich
Journal:  J Biol Chem       Date:  1998-11-20       Impact factor: 5.157

Review 8.  Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.

Authors:  Barbara Rehermann; Antonio Bertoletti
Journal:  Hepatology       Date:  2015-02       Impact factor: 17.425

9.  Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation.

Authors:  Ari B Molofsky; Frédéric Van Gool; Hong-Erh Liang; Steven J Van Dyken; Jesse C Nussbaum; Jinwoo Lee; Jeffrey A Bluestone; Richard M Locksley
Journal:  Immunity       Date:  2015-06-16       Impact factor: 31.745

10.  L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.

Authors:  Roger Geiger; Jan C Rieckmann; Tobias Wolf; Camilla Basso; Yuehan Feng; Tobias Fuhrer; Maria Kogadeeva; Paola Picotti; Felix Meissner; Matthias Mann; Nicola Zamboni; Federica Sallusto; Antonio Lanzavecchia
Journal:  Cell       Date:  2016-10-13       Impact factor: 41.582

View more
  12 in total

1.  Redox regulation of hepatic NLRP3 inflammasome activation and immune dysregulation in trichloroethene-mediated autoimmunity.

Authors:  Hui Wang; Gangduo Wang; Yuejin Liang; Xiaotang Du; Paul J Boor; Jiaren Sun; M Firoze Khan
Journal:  Free Radic Biol Med       Date:  2019-08-13       Impact factor: 7.376

2.  Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Sabrin Albeituni; Katherine C Verbist; Paige E Tedrick; Heather Tillman; Jennifer Picarsic; Rachel Bassett; Kim E Nichols
Journal:  Blood       Date:  2019-04-23       Impact factor: 22.113

3.  Retinoic Acid Modulates Hyperactive T Cell Responses and Protects Vitamin A-Deficient Mice against Persistent Lymphocytic Choriomeningitis Virus Infection.

Authors:  Yuejin Liang; Panpan Yi; Xiaofang Wang; Biao Zhang; Zuliang Jie; Lynn Soong; Jiaren Sun
Journal:  J Immunol       Date:  2020-04-13       Impact factor: 5.422

4.  Treatment With Endothelin-A Receptor Antagonist BQ123 Attenuates Acute Inflammation in Mice Through T-Cell-Dependent Polymorphonuclear Myeloid-Derived Suppressor Cell Activation.

Authors:  Ziyang Chen; Xiaogang Zhang; Shuaijun Lv; Zhe Xing; Mengyu Shi; Xinyao Li; Meiqi Chen; Shaowen Zuo; Yingxu Tao; Gang Xiao; Jingping Liu; Yumei He
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

Review 5.  The Interactions Between Autoinflammation and Type 2 Immunity: From Mechanistic Studies to Epidemiologic Associations.

Authors:  McKella Sylvester; Aran Son; Daniella M Schwartz
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

Review 6.  The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape.

Authors:  Mi-Ran Choi; Jeffrey A Sosman; Bin Zhang
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639

Review 7.  The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity.

Authors:  Claudia Afferni; Carla Buccione; Sara Andreone; Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone; Fabrizio Mattei; Giovanna Schiavoni
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

8.  IL-22 hinders antiviral T cell responses and exacerbates ZIKV encephalitis in immunocompetent neonatal mice.

Authors:  Yuejin Liang; Panpan Yi; Wenjuan Ru; Zuliang Jie; Hui Wang; Tamer Ghanayem; Xiaofang Wang; Edrous Alamer; Jinjun Liu; Haitao Hu; Lynn Soong; Jiyang Cai; Jiaren Sun
Journal:  J Neuroinflammation       Date:  2020-08-25       Impact factor: 8.322

Review 9.  Neutrophils in liver diseases: pathogenesis and therapeutic targets.

Authors:  Kai Liu; Fu-Sheng Wang; Ruonan Xu
Journal:  Cell Mol Immunol       Date:  2020-11-06       Impact factor: 11.530

10.  Group-2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression.

Authors:  Xingyuan Xu; Longyun Ye; Qi Zhang; Hang Shen; Shanshan Li; Xiaoyu Zhang; Mao Ye; Tingbo Liang
Journal:  Hepatology       Date:  2021-10-04       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.